US20140073616A1 - Hydrocortisone nanotechnological delivery system - Google Patents
Hydrocortisone nanotechnological delivery system Download PDFInfo
- Publication number
- US20140073616A1 US20140073616A1 US13/610,138 US201213610138A US2014073616A1 US 20140073616 A1 US20140073616 A1 US 20140073616A1 US 201213610138 A US201213610138 A US 201213610138A US 2014073616 A1 US2014073616 A1 US 2014073616A1
- Authority
- US
- United States
- Prior art keywords
- composition
- hydrocortisone
- resveratrol
- shampoo
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 title claims abstract description 79
- 229960000890 hydrocortisone Drugs 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 112
- 229940016667 resveratrol Drugs 0.000 claims abstract description 38
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 37
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 37
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 37
- 239000002453 shampoo Substances 0.000 claims abstract description 29
- 239000004094 surface-active agent Substances 0.000 claims abstract description 17
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 239000000787 lecithin Substances 0.000 claims description 9
- 235000010445 lecithin Nutrition 0.000 claims description 9
- 229940067606 lecithin Drugs 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229940007636 sodium lauroyl methyl isethionate Drugs 0.000 claims description 6
- NVIZQHFCDBQNPH-UHFFFAOYSA-M sodium;2-dodecanoyloxypropane-1-sulfonate Chemical group [Na+].CCCCCCCCCCCC(=O)OC(C)CS([O-])(=O)=O NVIZQHFCDBQNPH-UHFFFAOYSA-M 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 210000004761 scalp Anatomy 0.000 claims description 4
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical group C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 229960001067 hydrocortisone acetate Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 230000037317 transdermal delivery Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 14
- 239000002585 base Substances 0.000 description 10
- 238000013019 agitation Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940100608 glycol distearate Drugs 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 244000018436 Coriandrum sativum Species 0.000 description 4
- 235000002787 Coriandrum sativum Nutrition 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- KVWWIYGFBYDJQC-UHFFFAOYSA-N methyl dihydrojasmonate Chemical compound CCCCCC1C(CC(=O)OC)CCC1=O KVWWIYGFBYDJQC-UHFFFAOYSA-N 0.000 description 4
- 235000005282 vitamin D3 Nutrition 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- 239000011647 vitamin D3 Substances 0.000 description 4
- 229940021056 vitamin d3 Drugs 0.000 description 4
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 3
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229940100242 glycol stearate Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 229940101267 panthenol Drugs 0.000 description 3
- 235000020957 pantothenol Nutrition 0.000 description 3
- 239000011619 pantothenol Substances 0.000 description 3
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- KHLFMZDGADSQGR-ACCUITESSA-N (3e)-1-oxacyclohexadec-3-en-2-one Chemical compound O=C/1OCCCCCCCCCCCC\C=C\1 KHLFMZDGADSQGR-ACCUITESSA-N 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- OHRBQTOZYGEWCJ-UHFFFAOYSA-N 3-(3-propan-2-ylphenyl)butanal Chemical compound CC(C)C1=CC=CC(C(C)CC=O)=C1 OHRBQTOZYGEWCJ-UHFFFAOYSA-N 0.000 description 2
- YVSNOTITPICPTB-UHFFFAOYSA-N 4-methyl-2-(2-methylpropyl)oxan-4-ol Chemical compound CC(C)CC1CC(C)(O)CCO1 YVSNOTITPICPTB-UHFFFAOYSA-N 0.000 description 2
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 2
- 244000052707 Camellia sinensis Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- XRHCAGNSDHCHFJ-UHFFFAOYSA-N Ethylene brassylate Chemical compound O=C1CCCCCCCCCCCC(=O)OCCO1 XRHCAGNSDHCHFJ-UHFFFAOYSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229940093468 ethylene brassylate Drugs 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- GTABBGRXERZUAH-UHFFFAOYSA-N hexadecan-1-ol;2-methyloxirane;oxirane Chemical compound C1CO1.CC1CO1.CCCCCCCCCCCCCCCCO GTABBGRXERZUAH-UHFFFAOYSA-N 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BOPPSUHPZARXTH-UHFFFAOYSA-N ocean propanal Chemical compound O=CC(C)CC1=CC=C2OCOC2=C1 BOPPSUHPZARXTH-UHFFFAOYSA-N 0.000 description 2
- 229940099404 potassium cocoate Drugs 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229940031688 sodium c14-16 olefin sulfonate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 2
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- -1 Methylisothiazolinone Propylene Glycol Chemical compound 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000007244 Zea mays Nutrition 0.000 description 1
- KZENBFUSKMWCJF-UHFFFAOYSA-N [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol Chemical compound S1C(CO)=CC=C1C1=CC=C(C=2SC(CO)=CC=2)O1 KZENBFUSKMWCJF-UHFFFAOYSA-N 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229940062909 amyl salicylate Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000017 cortisol group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- NYNCZOLNVTXTTP-UHFFFAOYSA-N ethyl 2-(1,3-dioxoisoindol-2-yl)acetate Chemical compound C1=CC=C2C(=O)N(CC(=O)OCC)C(=O)C2=C1 NYNCZOLNVTXTTP-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Definitions
- the skin surface of mammals is constructed to repel most molecules.
- the skin acts as a barrier to protect the interior of a mammal.
- Topical applications have been developed whereby various molecules are absorbed through the skin.
- transdermal drug delivery has become an increasingly popular method for, among other reasons, high levels of patient compliance.
- One method is to provide a carrier that assists in the transport of micron, sub-micron and nano sized particles through the layers of the epidermis.
- Safe and reproducible drug delivery can be achieved with deformable and stable nano-sized carriers.
- the nano-sized carriers encompass materials that to some degree deform the various pores in the skin allowing for the transport of materials through and contrary to the skins natural barrier configuration.
- hydrocortisone products are known for topical use, they typically are not used in shampoo formulations.
- the present invention encompasses a composition, a method of manufacture and a method of application of a nanotechnological delivery of hydrocortisone and resveratrol in a topical preparation.
- the invention is a composition for the nano technological delivery of a medicament in a shampoo base.
- the main component is hydrocortisone.
- Hydrocortisone as used herein, includes the organic freebase, salts, isomers, and racemates.
- hydrocortisone acetate is used.
- the composition contains hydrocortisone, resveratrol, and a surfactant.
- the composition contains hydrocortisone, and a sulfate free surfactant.
- the composition is formulated into a shampoo and the shampoo facilitates nano technological delivery of the hydrocortisone, resveratrol, lecithin, and glycerin through the skin of a user.
- the hydrocortisone is present in amounts of about 0.01 to 1.00 percent w/w and resveratrol is present in a resveratrol composition wherein the composition is 1% w/w resveratrol in a carrier base of glycerin and lecithin in an amount of approximately 0.01 to 1.00 percent w/w.
- resveratrol composition refers to a composition containing 1% resveratrol in a carrier of lecithin and glycerin. There is 0.01-1.00 percent w/w of the resveratrol composition in the total formulation.
- the resveratrol composition of 1.00% resveratrol w/w is in a carrier base consisting of lecithin and glycerin.
- composition of the present invention is formulated into a topical preparation as desired.
- the topical preparation includes, but is not limited to the aforementioned shampoo, cream, ointment, gel, lotion, and any other liquid, solution, suspension, mixture, emulsion, semi-solid or the like.
- One preferred surfactant is sodium lauroyl methyl isethionate and the composition is formulated to contain approximately 10 to 30 percent w/w.
- the present invention has discovered that through a unique ratio of hydrocortisone and resveratrol composition, the efficacy is enhanced. Efficacy being defined as the absorption into the skin.
- the hydrocortisone and resveratrol composition is present in a ratio of about 1:1-1:2.
- the hydrocortisone and the resveratrol composition are present in a ratio of about 1:0.1-1:2.
- the hydrocortisone and the resveratrol composition are present in a ratio of about 0.1:1-0.1:2.
- the method utilizes a nanotechnological delivery system containing the steps of: providing a composition according to the present invention; applying the composition to the skin of a mammal; and absorbing the composition.
- the absorbing includes leaving the composition on the skin. Water is used to rinse the composition from the skin of the mammal.
- the method encompasses providing the composition formulated and presented to a user as a shampoo. The shampoo is applied to the scalp, allowed to remain, and rinsed.
- the absorbing includes leaving the composition in place after the applying step for a period of time from 5-300 seconds.
- This method is further applicable to all skin surfaces and equally applicable when the topical composition formulated with nanotechnological delivery system of the present invention is formulated and presented as cream, ointment, gel, lotion, foam, paste, and any other liquid mixture such as aqueous mixture and/or aqueous-organic mixture, solution, suspension, mixture, emulsion, semi-solid and the like.
- the invention encompasses a transdermal delivery of a combined composition containing hydrocortisone and a resveratrol composition.
- Each of the hydrocortisone and resveratrol composition is formulated utilizing particular ratios that have been shown to have an advantageous synergistic effect in effectuating trans-dermal drug delivery.
- the present invention encompasses formulation of hydrocortisone and resveratrol in a shampoo composition.
- the composition includes a plurality of components to enhance the nanotechnological delivery of the active components through the skin.
- the shampoo has a formulation as in Table 1 below.
- a base when formulated as a shampoo, is prepared starting with acrylate crosspolymer-4 in water.
- acrylate crosspolymer-4 is selected based on the characteristics of imparting a desired viscosity and compatibly with the nanotechnology delivery components. This particular component in the above-stated range is particular for compatibility for both the active materials of hydrocortisone and resveratrol.
- a preferred acrylate crosspolymer-4 is Carbopol aqua SF-2 polymer (available from Lubrizol, Wickcliffe, Ohio). Additionally, the initial base is prepared with panthenol, caffeine and tetrasodium EDTA. Once the initial base is prepared and a solution is obtained, various components selected with particularity and criticality as to percentage composition and chemistry are added to the base.
- the next step includes adding glycol distearate, cocamide DEA, and cocamidoproplbetaine with glycerin. Additionally, glycol stearate, cocamide MEA, glycol distearate, sodium lauroyl methyl Isethionate, cholecalciferol and zea mays are added to the base.
- the surfactant of the present invention incorporates approximately 10 to 30 percent of sodium lauroyl sarcocinate.
- a preferred material is available from RITA Corporation and sold as RitaFactant LS-30. This material is selected with particularity as to composition and to percentage used in the formulation of the present invention in order to provide improved delivery of the active in a nanotechnology delivery system.
- micronized hydrocortisone is utilized. Hydrocortisone is present in a range of 0.1 to 1.0 percent w/w.
- the particular micronization properties require a preferred material that has a particle size of not less than 90 percent of the particles less than or equal to five microns. Although, as stated herein, 90% is less than 5 microns, it is generally understood in the art that particle size measurements are typically measured and presented as a Gaussian curve with the major portion of the curve demonstrating particle size between about 1 to 5 microns.
- the shampoo is produced in a method as now described.
- Steps 1-2 are at 78° C.-80° C., add, in order:
- Steps 1-6 Add the mixture from the second vessel to the main vessel (Steps 1-6) where the main vessel is at 40° C.
- the adding of the secondary vessel components are added to the main vessel under propeller agitation.
- step 7 When the mixture of step 7 is uniform, cool the batch to 35° C. and add:
- step 8 The materials in step 8 are added under propeller agitation.
- premix ingredients under propeller agitation and mix until clear and uniform.
- the phase can optionally be warmed to 40° C. while mixing:
- Steps 1-8) When the main product batch (Steps 1-8) is at 35° C., add premixed step 9 mixture to main product batch under propeller agitation. Mix until uniform.
- Vicosity can be measured in any acceptable manner including Dynamic and Kinematic measurements. A preferred measurement is using Brookfield RVT; Spindle: 4; Speed: 20 rpm; Time: 1 Minute).
- a NaCl solution is used as needed to adjust the viscosity to 3,500-5,000 cps.
- pH and viscosity are measured between 25° C. to 30° C. Care is taken, as it is known in the art that viscosity of surfactant-based compositions is correlated to a salt concentration gradient.
- the composition is cooled to 30° C. and discharge into suitable storage containers.
- the finished product exhibits the following characteristics:
- the present invention has discovered the enhanced nanotechnological delivery of a hydrocortisone-resveratrol composition based on the discovered base formulation and synergistic ratio of hydrocortisone:resveratrol composition. The result will provide enhanced absorption therapy over known compositions.
- the nanotechnolgical delivery system of the present invention is prepared as any of a cream, lotion, ointment, or gel.
- the cream will utilize the advantageous novel ratio of hydrocortisone, resveratrol, lecithin, and glycerin to deliver the actives in the novel nanotechnological delivery system discovered and disclosed herein.
- hydrocortisone formulated according to the present invention while omitting resveratrol maintains an acceptable level of efficacy for delivery though the skin.
Abstract
Description
- 1. Field of the Invention
- The skin surface of mammals is constructed to repel most molecules. The skin acts as a barrier to protect the interior of a mammal. Topical applications have been developed whereby various molecules are absorbed through the skin. In addition to topical applications, transdermal drug delivery has become an increasingly popular method for, among other reasons, high levels of patient compliance. There still exists a difficulty in transport of molecules through the various epidermal membranes in order to effectuate drug absorption through the skin. One method is to provide a carrier that assists in the transport of micron, sub-micron and nano sized particles through the layers of the epidermis. Safe and reproducible drug delivery can be achieved with deformable and stable nano-sized carriers. The nano-sized carriers encompass materials that to some degree deform the various pores in the skin allowing for the transport of materials through and contrary to the skins natural barrier configuration.
- Although hydrocortisone products are known for topical use, they typically are not used in shampoo formulations.
- The present invention encompasses a composition, a method of manufacture and a method of application of a nanotechnological delivery of hydrocortisone and resveratrol in a topical preparation.
- In one embodiment, the invention is a composition for the nano technological delivery of a medicament in a shampoo base. The main component is hydrocortisone. Hydrocortisone, as used herein, includes the organic freebase, salts, isomers, and racemates. In one embodiment hydrocortisone acetate is used. In one embodiment, the composition contains hydrocortisone, resveratrol, and a surfactant. In one embodiment, the composition contains hydrocortisone, and a sulfate free surfactant. The composition is formulated into a shampoo and the shampoo facilitates nano technological delivery of the hydrocortisone, resveratrol, lecithin, and glycerin through the skin of a user.
- The hydrocortisone is present in amounts of about 0.01 to 1.00 percent w/w and resveratrol is present in a resveratrol composition wherein the composition is 1% w/w resveratrol in a carrier base of glycerin and lecithin in an amount of approximately 0.01 to 1.00 percent w/w. As used herein, the term “resveratrol composition” refers to a composition containing 1% resveratrol in a carrier of lecithin and glycerin. There is 0.01-1.00 percent w/w of the resveratrol composition in the total formulation.
- In one embodiment, the resveratrol composition of 1.00% resveratrol w/w is in a carrier base consisting of lecithin and glycerin.
- Additionally, the composition of the present invention is formulated into a topical preparation as desired. The topical preparation includes, but is not limited to the aforementioned shampoo, cream, ointment, gel, lotion, and any other liquid, solution, suspension, mixture, emulsion, semi-solid or the like.
- One preferred surfactant is sodium lauroyl methyl isethionate and the composition is formulated to contain approximately 10 to 30 percent w/w.
- The present invention has discovered that through a unique ratio of hydrocortisone and resveratrol composition, the efficacy is enhanced. Efficacy being defined as the absorption into the skin. In one embodiment the hydrocortisone and resveratrol composition is present in a ratio of about 1:1-1:2.
- In another embodiment, the hydrocortisone and the resveratrol composition are present in a ratio of about 1:0.1-1:2.
- In another embodiment, the hydrocortisone and the resveratrol composition are present in a ratio of about 0.1:1-0.1:2.
- Also contemplated is a method of delivering an active component through the skin of a mammal. The method utilizes a nanotechnological delivery system containing the steps of: providing a composition according to the present invention; applying the composition to the skin of a mammal; and absorbing the composition. The absorbing includes leaving the composition on the skin. Water is used to rinse the composition from the skin of the mammal. In a preferred embodiment, the method encompasses providing the composition formulated and presented to a user as a shampoo. The shampoo is applied to the scalp, allowed to remain, and rinsed.
- The absorbing includes leaving the composition in place after the applying step for a period of time from 5-300 seconds.
- This method is further applicable to all skin surfaces and equally applicable when the topical composition formulated with nanotechnological delivery system of the present invention is formulated and presented as cream, ointment, gel, lotion, foam, paste, and any other liquid mixture such as aqueous mixture and/or aqueous-organic mixture, solution, suspension, mixture, emulsion, semi-solid and the like.
- The invention encompasses a transdermal delivery of a combined composition containing hydrocortisone and a resveratrol composition. Each of the hydrocortisone and resveratrol composition is formulated utilizing particular ratios that have been shown to have an advantageous synergistic effect in effectuating trans-dermal drug delivery. In a preferred embodiment, the present invention encompasses formulation of hydrocortisone and resveratrol in a shampoo composition. The composition includes a plurality of components to enhance the nanotechnological delivery of the active components through the skin.
- In one embodiment, the shampoo has a formulation as in Table 1 below.
-
TABLE 1 Component % w/w Water 20.0-50.0 Acrylates Crosspolymer-4 0.1-10.0 Panthenol 0.00001-0.1 Caffeine 0.00001-0.1 Tetrasodium EDTA 0.01-0.5 Glycol Distearate (and) Cocamide DEA 0.01-1.0 (and) CocamidopropylBetaine (and) Glycerin Glycol Stearate 0.1-10.0 Cocamide MEA 0.1-10.0 Glycol Distearate 0.1-10.0 Sodium Lauroyl Methyl Isethionate 0.1-10.0 Cholecalciferol (and) Zea Mays (Corn) Oil 0.00001-0.1 Sodium Lauroyl Sarcocinate 10.0-30.0 Sodium C14-16 Olefin Sulfonate 0.1-10.0 Potassium Cocoate 0.1-10.0 CocamidopropylBetaine 5.0-20.0 Polyquaternium-39 0.1-10.0 DMDM Hydantoin 0.1-1.0 Methylchloroisothiazolinone (and) 0.00001-0.09 Methylisothiazolinone Propylene Glycol 0.1-10.0 Camellia Sinensis Leaf Extract (and) 0.00001-0.1 Water (and) Glycerin Tocopheryl Acetate 0.00001-0.1 Magnesium Ascorbyl Phosphate 0.00001-0.1 RetinylPalmitate 0.00001-0.1 Methyldihydrojasmonate (and) Amyl 0.1-2.0 Salicylate (and) Isobutyl Methyl Tetrahydropyranol (and) Ethylene Brassylate (and) 2,-Dimethyl-7- Octen-2-OL (and) Linalool (and) TetramethylAcetyloctahydronaphthalenes (and) Phenethyl Alcohol (and) Oxacyclohexadecenone (and) MethylenedioxyphenylMethylpropanal (and) CoriandrumSativum (Coriander) Fruit Oil (and) Isopropylphenylbutanal (and) Decanal PPG-5 Ceteth-20 0.1-2.0 Styrene/Acrylates Copolymer 0.01-1.0 Citric Acid [50%] (and) Water [50%] 0.01-1.0 Sodium Chloride 0.01-1.0 With active components of Hydrocortisone 0.01-1.00 Resveratrol Composition 0.01-1.00. - In a preferred embodiment, when formulated as a shampoo, a base is prepared starting with acrylate crosspolymer-4 in water. Although many materials are suitable and known for shampoo formulation in general and particularly for a formulation with a desired viscosity, the selected acrylate crosspolymer-4 is selected based on the characteristics of imparting a desired viscosity and compatibly with the nanotechnology delivery components. This particular component in the above-stated range is particular for compatibility for both the active materials of hydrocortisone and resveratrol.
- A preferred acrylate crosspolymer-4 is Carbopol aqua SF-2 polymer (available from Lubrizol, Wickcliffe, Ohio). Additionally, the initial base is prepared with panthenol, caffeine and tetrasodium EDTA. Once the initial base is prepared and a solution is obtained, various components selected with particularity and criticality as to percentage composition and chemistry are added to the base.
- The next step includes adding glycol distearate, cocamide DEA, and cocamidoproplbetaine with glycerin. Additionally, glycol stearate, cocamide MEA, glycol distearate, sodium lauroyl methyl Isethionate, cholecalciferol and zea mays are added to the base.
- Although it is well known in the art that there are numerous surfactant bases suitable for shampoos in general and medical shampoos in particular, it has been discovered in formulas of the present invention that in order to deliver hydrocortisone and resveratrol utilizing a nano technology delivery system a sulfate free surfactant needs to be utilized. In a preferred embodiment the surfactant of the present invention incorporates approximately 10 to 30 percent of sodium lauroyl sarcocinate. A preferred material is available from RITA Corporation and sold as RitaFactant LS-30. This material is selected with particularity as to composition and to percentage used in the formulation of the present invention in order to provide improved delivery of the active in a nanotechnology delivery system.
- In a preferred embodiment micronized hydrocortisone is utilized. Hydrocortisone is present in a range of 0.1 to 1.0 percent w/w. The particular micronization properties require a preferred material that has a particle size of not less than 90 percent of the particles less than or equal to five microns. Although, as stated herein, 90% is less than 5 microns, it is generally understood in the art that particle size measurements are typically measured and presented as a Gaussian curve with the major portion of the curve demonstrating particle size between about 1 to 5 microns.
- In a preferred embodiment, the shampoo is produced in a method as now described.
- Step 1
- Add ingredients
- Water,
- Acrylates Crosspolymer-4,
- Panthenol,
- Caffeine, and
- Tetrasodium EDTA—in order in a suitable main kettle and mixed under propeller agitation.
- Start heating ingredients to 78° C.-80° C.
- Step 2
- Once desired temperature is reached, add the following while maintaining temperature and mixing.
- Glycol Distearate,
- Cocamide DEA,
- CocamidopropylBetaine,
- Glycerin,
- Glycol Stearate,
- Cocamide MEA,
- Glycol Distearate,
- Sodium Lauroyl Methyl Isethionate,
- Cholecalciferol,and
- Zea Mays (Corn) Oil.
- Step 3
- Once Steps 1-2 are at 78° C.-80° C., add, in order:
- Sodium Lauroyl Sarcocinate,
- Sodium C14-16 Olefin Sulfonate,and
- Potassium Cocoate.
- Continue to mix until all ingredients are dissolved and maintain temperature at 78° C.-80° C.
- Step 4
- When a uniform mixture is achieved, cool the batch to 70° C.-75° C. When the batch is 70°-75° C., add:
- CocamidopropylBetaine—under propeller agitation and mix until uniform.
- Step 5
- When a uniform mixture is achieved, cool the mixture to 45° C.-50° C.
- Then add, while mixing—Polyquaternium-39.
- Mix until uniform.
- Step 6
- When a uniform mixture is achieved, cool the mixture 40° C. and add:
- DMDM Hydantoin,
- Methylchloroisothiazolinone, and
- Methyl isothiazolinone.
- Added in order under propeller agitation. Mix until uniform.
- Step 7
- In a second, or auxiliary vessel, premix the following ingredients in advance under homogenizer agitation and mix until thoroughly dispersed:
- Propylene Glycol,
- Hydrocortisone,
- Reservatrol,
- Glycerin, and
- Lecithin.
- Add the mixture from the second vessel to the main vessel (Steps 1-6) where the main vessel is at 40° C. The adding of the secondary vessel components are added to the main vessel under propeller agitation.
- Step 8
- When the mixture of step 7 is uniform, cool the batch to 35° C. and add:
- Camellia Sinensis Leaf Extract (and) Water (and) Glycerin,
- Tocopheryl Acetate,
- Magnesium Ascorbyl Phosphate,
- RetinylPalmitate, and
- Cholecalciferol (and) Zea Mays (Corn) Oil.
- The materials in step 8 are added under propeller agitation.
- Step 9
- In a third vessel, premix ingredients under propeller agitation and mix until clear and uniform. The phase can optionally be warmed to 40° C. while mixing:
- Methyldihydrojasmonate,
- Amyl Salicylate,
- Isobutyl Methyl Tetrahydropyranol,
- Ethylene Brassylate,
- 2,-Dimethyl-7-Octen-2-OL,
- Linalool,
- TetramethylAcetyloctahydronaphthalenes,
- Phenethyl Alcohol,
- Oxacyclohexadecenone,
- MethylenedioxyphenylMethylpropanal,
- CoriandrumSativum (Coriander) Fruit Oil Isopropylphenylbutanal,
- Decanal,
- PPG-5 Ceteth-20, and
- Styrene/Acrylates Copolymer.
- Step 10
- When the main product batch (Steps 1-8) is at 35° C., add premixed step 9 mixture to main product batch under propeller agitation. Mix until uniform.
- Step 11
- When the batch is uniform, add styrene/Acrylates Copolymer and mix until uniform.
- Step 12
- When the batch is uniform, take the pH of the batch and use (Citric Acid 50% Solution) to adjust the pH to 5.50-6.00.
- Step 13
- After the pH has been adjusted, take the viscosity of the batch. Vicosity can be measured in any acceptable manner including Dynamic and Kinematic measurements. A preferred measurement is using Brookfield RVT; Spindle: 4; Speed: 20 rpm; Time: 1 Minute).
- A NaCl solution is used as needed to adjust the viscosity to 3,500-5,000 cps. Each of pH and viscosity are measured between 25° C. to 30° C. Care is taken, as it is known in the art that viscosity of surfactant-based compositions is correlated to a salt concentration gradient.
- Step 14
- When the viscosity is either in the desired range or has been adjusted into the desired range, the composition is cooled to 30° C. and discharge into suitable storage containers.
- In one embodiment, the finished product exhibits the following characteristics:
-
Viscosity, initial Brookfield RVT; Spindle: 4; Speed: 20 RPM; Time: 1 Minute 3,500-5,000 cps Viscosity, 24 hr Brookfield RVT; Spindle: 4; Speed: 20 RPM; Time: 1 Minute 4,000-6,000 cps Specific Gravity Pycnometer 1.020 +/− 0.02 pH 5.50-6.50 24 hr Stability @ 45° C. Observation Stable - No separation Microbiology Test 1 Total Aerobic Microbial Count <=100 ufc/g Microbiology Test 2 Salmonella, Escherichia Coli, Pseudomonas Aruginosa, Staphylococcus Aureus None - The present invention has discovered the enhanced nanotechnological delivery of a hydrocortisone-resveratrol composition based on the discovered base formulation and synergistic ratio of hydrocortisone:resveratrol composition. The result will provide enhanced absorption therapy over known compositions.
- In one embodiment, the nanotechnolgical delivery system of the present invention is prepared as any of a cream, lotion, ointment, or gel. The cream will utilize the advantageous novel ratio of hydrocortisone, resveratrol, lecithin, and glycerin to deliver the actives in the novel nanotechnological delivery system discovered and disclosed herein.
- In one embodiment, it has further been discovered that hydrocortisone formulated according to the present invention, while omitting resveratrol maintains an acceptable level of efficacy for delivery though the skin.
- While the invention has been described in its preferred form or embodiment with some degree of particularity, it is understood that this description has been given only by way of example and that numerous changes in the details of construction, fabrication, and use, including the combination and arrangement of parts, may be made without departing from the spirit and scope of the invention.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/610,138 US9205093B2 (en) | 2012-09-11 | 2012-09-11 | Hydrocortisone nanotechnological delivery system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/610,138 US9205093B2 (en) | 2012-09-11 | 2012-09-11 | Hydrocortisone nanotechnological delivery system |
Publications (2)
Publication Number | Publication Date |
---|---|
US20140073616A1 true US20140073616A1 (en) | 2014-03-13 |
US9205093B2 US9205093B2 (en) | 2015-12-08 |
Family
ID=50233879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/610,138 Active 2033-01-16 US9205093B2 (en) | 2012-09-11 | 2012-09-11 | Hydrocortisone nanotechnological delivery system |
Country Status (1)
Country | Link |
---|---|
US (1) | US9205093B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9861645B2 (en) | 2012-12-28 | 2018-01-09 | Rak Holdings Llc | Anti-itch scalp treatment compositions and combinations |
WO2021058977A1 (en) * | 2019-09-27 | 2021-04-01 | Hewlett Healthcare Limited | Formulation |
US20220105237A1 (en) * | 2019-02-04 | 2022-04-07 | Maruho Co., Ltd. | Skin composition |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722837A (en) * | 1984-05-29 | 1988-02-02 | Derma-Cure, Inc. | Medicated shampoo composition |
US4835148A (en) * | 1986-02-24 | 1989-05-30 | The Procter & Gamble Co. | Shampoo compositions comprising water-insoluble particulate anti-inflammatory agents |
WO1994009763A1 (en) * | 1992-11-04 | 1994-05-11 | Unilever Plc | Improvements relating to substituted isethionate surfactants and personal care compositions comprising said surfactants |
US5436010A (en) * | 1993-07-30 | 1995-07-25 | Sdg Technology, Inc. | Hair penetrant and carrier |
US5653989A (en) * | 1993-12-27 | 1997-08-05 | Galderma S.A. | Water-in oil lotion containing corticosteroid |
WO1999004747A2 (en) * | 1997-07-25 | 1999-02-04 | Unilever Plc | Cosmetic compositions |
US20030228269A1 (en) * | 2000-06-02 | 2003-12-11 | Derosa Mario | Use of stilbene derivatives for dandruff treatment |
US20080234159A1 (en) * | 2004-01-20 | 2008-09-25 | Huntsman Petrochemical Corporation | Novel Acylalkylisethionate Esters and Applications in Consumer Products |
WO2009074239A1 (en) * | 2007-12-12 | 2009-06-18 | Monteresearch-Pharmaceutical Development Service | Pharmaceutical foams |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2316312B1 (en) * | 2008-06-20 | 2010-02-08 | Ignacio Umbert Millet | DERMATOLOGICAL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SKIN INFLAMMATION PATHOLOGIES, SUCH AS FOR EXAMPLE DERMATITIS, ATOPICA DERMATITIS, VITILIGO, AREATA ALOPECIA, ACNE, PSORIASIS AND PRURITO, AND COMBINATIONS OF THE SAME. |
CN101579291B (en) * | 2009-05-20 | 2011-06-15 | 清华大学 | Resveratrol phospholipid composite nano-emulsion and preparation method and application thereof |
-
2012
- 2012-09-11 US US13/610,138 patent/US9205093B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722837A (en) * | 1984-05-29 | 1988-02-02 | Derma-Cure, Inc. | Medicated shampoo composition |
US4835148A (en) * | 1986-02-24 | 1989-05-30 | The Procter & Gamble Co. | Shampoo compositions comprising water-insoluble particulate anti-inflammatory agents |
WO1994009763A1 (en) * | 1992-11-04 | 1994-05-11 | Unilever Plc | Improvements relating to substituted isethionate surfactants and personal care compositions comprising said surfactants |
US5436010A (en) * | 1993-07-30 | 1995-07-25 | Sdg Technology, Inc. | Hair penetrant and carrier |
US5653989A (en) * | 1993-12-27 | 1997-08-05 | Galderma S.A. | Water-in oil lotion containing corticosteroid |
WO1999004747A2 (en) * | 1997-07-25 | 1999-02-04 | Unilever Plc | Cosmetic compositions |
US20030228269A1 (en) * | 2000-06-02 | 2003-12-11 | Derosa Mario | Use of stilbene derivatives for dandruff treatment |
US20080234159A1 (en) * | 2004-01-20 | 2008-09-25 | Huntsman Petrochemical Corporation | Novel Acylalkylisethionate Esters and Applications in Consumer Products |
WO2009074239A1 (en) * | 2007-12-12 | 2009-06-18 | Monteresearch-Pharmaceutical Development Service | Pharmaceutical foams |
Non-Patent Citations (2)
Title |
---|
Bentley, M.V.L.B., et al., International Journal of Pharmaceutics Vol. 146, pages 255-262. Published 1997. * |
Cocamide MEA product page (Kao Chemicals Europe, published 1994). * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9861645B2 (en) | 2012-12-28 | 2018-01-09 | Rak Holdings Llc | Anti-itch scalp treatment compositions and combinations |
US20220105237A1 (en) * | 2019-02-04 | 2022-04-07 | Maruho Co., Ltd. | Skin composition |
WO2021058977A1 (en) * | 2019-09-27 | 2021-04-01 | Hewlett Healthcare Limited | Formulation |
GB2587402B (en) * | 2019-09-27 | 2023-05-10 | Hewlett Healthcare Ltd | Formulation |
Also Published As
Publication number | Publication date |
---|---|
US9205093B2 (en) | 2015-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10441552B2 (en) | Anti-microbial composition comprising cannabinoids | |
CN100366244C (en) | Local used composition containing antifungal agent | |
CN108472513B (en) | Hair growth compositions and methods | |
JP6745721B2 (en) | Composition | |
WO2020028820A1 (en) | Topical compositions and methods of preparation and use | |
JP2021527037A (en) | Roflumilast Methods and Formulations to Improve Skin Penetration Ragtime | |
CN104490782A (en) | Temperature control foaming agent for external use, making method thereof and application thereof | |
US9205093B2 (en) | Hydrocortisone nanotechnological delivery system | |
JP6385938B2 (en) | Topical steroid compositions and methods | |
JP2022085808A (en) | Animal shampoo with antibacterial function and manufacturing method thereof | |
ES2377616B1 (en) | STABILIZING COMPOSITION FOR TOPICAL APPLICATION FORMULATIONS AND USING THE SAME. | |
US11395827B2 (en) | Oil-in-water emulsion of mometasone and propylene glycol | |
JP2022501314A (en) | Topical composition | |
US11813240B1 (en) | Method of using microemulsion, and method of treating fungal infection | |
US9132291B2 (en) | Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa | |
Hamid et al. | Formulation and evaluation of benzyl benzoate emulgel | |
US8372440B2 (en) | Antifungal foam containing ciclopiroxolamine and zinc pyrithione and medical and cosmetic applications thereof | |
Bhaskar et al. | A Review On: Ointment and Ointment Bases | |
US20180228723A1 (en) | Oil-in-water emulsion of mometasone | |
Kudrik et al. | Development of the composition of foamy washing liquid with an extract of pollen for use in pediatrics | |
US20230037905A1 (en) | Topical composition comprising tofacitinib and fingolimod | |
JP6084579B2 (en) | Oil-in-water cream composition containing tacrolimus | |
JP2006117539A (en) | Oily ointment | |
US20200337963A1 (en) | No rinse hand cleansing composition | |
RU2022104310A (en) | COMPOSITIONS FOR TOPICAL APPLICATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: 7.5 YR SURCHARGE - LATE PMT W/IN 6 MO, SMALL ENTITY (ORIGINAL EVENT CODE: M2555); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 8 |